

Albert D Windhorst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2993968/publications.pdf>

Version: 2024-02-01

263
papers

9,397
citations

44069

48
h-index

54911

84
g-index

280
all docs

280
docs citations

280
times ranked

11677
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1951-1963.	6.4	8
2	Genetically identical twins show comparable tau PET load and spatial distribution. <i>Brain</i> , 2022, 145, 3571-3581.	7.6	12
3	Folate Receptor Beta for Macrophage Imaging in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 819163.	4.8	8
4	The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor. <i>Pharmaceuticals</i> , 2022, 15, 450.	3.8	6
5	Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [⁸⁹ Zr]Zr-DFO-PEG ₅ -Tz. <i>Bioconjugate Chemistry</i> , 2022, 33, 956-968.	3.6	2
6	Novel application of [18F]DPA714 for visualizing the pulmonary inflammation process of SARS-CoV-2-infection in rhesus monkeys (<i>Macaca mulatta</i>). <i>Nuclear Medicine and Biology</i> , 2022, 112-113, 1-8.	0.6	3
7	Phase I Trial of ¹³¹ I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1097-1105.	5.0	67
8	Repeatability of parametric methods for [¹⁸ F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 569-578.	4.3	10
9	The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 140-149.	4.7	14
10	Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. <i>Clinical Cancer Research</i> , 2021, 27, 189-201.	7.0	106
11	The Role of ⁸⁹ Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. <i>Journal of Nuclear Medicine</i> , 2021, 62, 438-445.	5.0	39
12	Grey zone amyloid burden affects memory function: the SCIENCE project. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 747-756.	6.4	5
13	Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical ⁸⁹ Zr-immuno-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 694-707.	6.4	43
14	Synchronizing chemistry, quantum mechanics and radioactivity in a revolutionary renewed atom model. Part 1: the elements where Z is 1 ≤ Z ≤ 10 (H, He, Li, Be, B, C, N, O, F, Ne). <i>RSC Advances</i> , 2021, 11, 27978-27991.	3.6	0
15	Fluorine-18 labelled Ruppert-Prakash reagent ([¹⁸ F]Me ₃ SiCF ₃) for the synthesis of ¹⁸ F-trifluoromethylated compounds. <i>Chemical Communications</i> , 2021, 57, 5286-5289.	4.1	8
16	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.	2.6	2
17	In vivo tau pathology is associated with synaptic loss and altered synaptic function. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 35.	6.2	47
18	Performance of nanoScan PET/CT and PET/MR for quantitative imaging of ¹⁸ F and ⁸⁹ Zr as compared with ex vivo biodistribution in tumor-bearing mice. <i>EJNMMI Research</i> , 2021, 11, 57.	2.5	6

#	ARTICLE	IF	CITATIONS
19	[¹⁸ F]Flortaucipir PET Across Various <i>MAPT</i> Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.1	16
20	Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 42, 116245.	3.0	8
21	Towards PET imaging of the dynamic phenotypes of microglia. <i>Clinical and Experimental Immunology</i> , 2021, 206, 282-300.	2.6	28
22	The role of neuroimaging in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021, 159, 660-689.	3.9	35
23	BLZ945 derivatives for PET imaging of colony stimulating factor-1 receptors in the brain. <i>Nuclear Medicine and Biology</i> , 2021, 100-101, 44-51.	0.6	10
24	Evaluating N-ethyl-2-(2-difluoromethyltriazolium triflate) as a precursor for the synthesis of high molar activity [¹⁸ F]fluoroform. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 466-476.	1.0	5
25	Comparison of analytical methods for antibody conjugates with application in nuclear imaging – Report from the trenches. <i>Nuclear Medicine and Biology</i> , 2021, 102-103, 24-33.	0.6	1
26	State of the art of radiochemistry for ¹¹ C and ¹⁸ F PET tracers. , 2021, , .		0
27	PET Imaging of Purinergic Receptors. , 2021, , 879-889.		1
28	Synthesis and evaluation of [¹⁸ F]cinacalcet for the imaging of parathyroid hyperplasia. <i>Nuclear Medicine and Biology</i> , 2021, 102-103, 97-105.	0.6	2
29	Neuroinflammation: From Target Selection to Preclinical and Clinical Studies. , 2021, , 567-592.		1
30	Novel Thienopyrimidine-Based PET Tracers for P2Y ₁₂ Receptor Imaging in the Brain. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4465-4474.	3.5	15
31	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. <i>Cancers</i> , 2021, 13, 6088.	3.7	8
32	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
33	Parametric methods for [¹⁸ F]flortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 365-373.	4.3	22
34	The P2X7 receptor tracer [¹¹ C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 379-389.	6.4	44
35	Hippocampal [¹⁸ F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. <i>NeuroImage: Clinical</i> , 2020, 25, 102113.	2.7	5
36	Why Is Amyloid- β PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	2.6	8

#	ARTICLE	IF	CITATIONS
37	Design, Synthesis, Conjugation, and Reactivity of Novel <i>cis,trans</i> -1,5-Cyclooctadiene-Derived Bioorthogonal Linkers. <i>Bioconjugate Chemistry</i> , 2020, 31, 2201-2210.	3.6	6
38	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [¹¹ C]SMW139. <i>Journal of Neuroinflammation</i> , 2020, 17, 300.	7.2	15
39	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. <i>NeuroImage: Clinical</i> , 2020, 28, 102504.	2.7	14
40	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041048.	0.8	2
41	Early-onset Alzheimer's disease is related to differential spatial patterns of tau pathology and cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042041.	0.8	0
42	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [¹⁸ F]flortaucipir, [¹¹ C]UCB-J and magnetoencephalography study. <i>Alzheimer's and Dementia</i> , 2020, 16, e045806.	0.8	0
43	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045876.	0.8	0
44	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3165-3175.	6.4	28
45	Design, Synthesis, Radiosynthesis and Biological Evaluation of Fenretinide Analogues as Anticancer and Metabolic Syndrome-Preventive Agents. <i>ChemMedChem</i> , 2020, 15, 1579-1590.	3.2	2
46	Quantification of PD-L1 Expression with ¹⁸ F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1455-1460.	5.0	54
47	First in man study of [¹⁸ F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 1047.	3.3	43
48	Synthesis of [¹⁸ F]Fluoroform with High Molar Activity. <i>European Journal of Organic Chemistry</i> , 2020, 2020, 1177-1185.	2.4	17
49	Preclinical Targeted α - and β -Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. <i>Cancers</i> , 2020, 12, 1017.	3.7	43
50	Regional [¹⁸ F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	6.4	29
51	Quantification of [¹⁸ F]florbetapir: A test-retest kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2172-2180.	4.3	22
52	In vivo imaging of TGF β signalling components using positron emission tomography. <i>Drug Discovery Today</i> , 2019, 24, 2258-2272.	6.4	6
53	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 7.	3.9	9
54	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	6.2	40

#	ARTICLE	IF	CITATIONS
55	Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. PLoS ONE, 2019, 14, e0222844.	2.5	17
56	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Clinical and Translational Imaging, 2019, 7, 61-63.	2.1	3
57	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
58	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	2.4	9
59	Status of the ~consensus nomenclature rules in radiopharmaceutical sciences™ initiative. Nuclear Medicine and Biology, 2019, 71, 19-22.	0.6	7
60	Simplified Methods for Quantification of ¹⁸ F-DCFPyL Uptake in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1730-1735.	5.0	32
61	Binding characterization of N-(2-chloro-5-thiomethylphenyl)-N-(3-[³ H] methoxy phenyl)-N-methylguanidine ([³ H] GMOM), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Pharmacology Research and Perspectives, 2019, 7, e00458.		3
62	Assessment of Simplified Methods for Quantification of ¹⁸ F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1221-1227.	5.0	10
63	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. Neurobiology of Aging, 2019, 79, 50-58.	3.1	41
64	PET and CSF amyloid- β^2 status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
65	Fully Automated ⁸⁹ Zr Labeling and Purification of Antibodies. Journal of Nuclear Medicine, 2019, 60, 691-695.	5.0	19
66	Evaluation of the Novel PET Tracer [¹¹ C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. Molecular Imaging and Biology, 2019, 21, 676-685.	2.6	8
67	From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application. Molecular Imaging and Biology, 2018, 20, 510-532.	2.6	22
68	Open letter to journal editors on. Nuclear Medicine Communications, 2018, 39, 193-195.	1.1	0
69	Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. Journal of Radioanalytical and Nuclear Chemistry, 2018, 315, 443-445.	1.5	0
70	Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 402-404.	1.0	5
71	Identification of the allosteric P2X7 receptor antagonist [¹¹ C]SMW139 as a PET tracer of microglial activation. Scientific Reports, 2018, 8, 6580.	3.3	54
72	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Annals of Nuclear Medicine, 2018, 32, 236-238.	2.2	23

#	ARTICLE	IF	CITATIONS
73	International Consensus Radiochemistry Nomenclature Guidelines. Radiochimica Acta, 2018, 106, 623-625.	1.2	1
74	ICâ€Pâ€222: [¹⁸ F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.8	0
75	P3â€438: PARAMETRIC IMAGING OF [¹⁸ F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.8	0
76	P2â€360: [¹⁸ F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.8	0
77	First in human evaluation of [¹⁸ F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors. EJNMMI Research, 2018, 8, 69.	2.5	9
78	Quantification of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Research, 2018, 8, 72.	2.5	14
79	Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([¹⁸ F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 11.	3.9	4
80	In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model. EJNMMI Research, 2018, 8, 39.	2.5	5
81	A novel partial volume correction method for accurate quantification of [¹⁸ F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	2.5	19
82	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [¹⁸ F]DPA714 PET. Journal of Neuroinflammation, 2018, 15, 314.	7.2	64
83	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications, 2018, 9, 4664.	12.8	331
84	Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state. Theranostics, 2018, 8, 5400-5418.	10.0	48
85	Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P_{1â€7}. Molecular Pharmaceutics, 2018, 15, 4872-4883.	4.6	1
86	Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [¹⁸ F]Fluoro-PEG-Folate. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.8	17
87	PET Imaging of Microglial Activationâ€”Beyond Targeting TSPO. Molecules, 2018, 23, 607.	3.8	85
88	Improving metabolic stability of fluorine-18 labeled verapamil analogs. Nuclear Medicine and Biology, 2018, 64-65, 47-56.	0.6	7
89	Fast and reliable generation of [¹⁸ F]triflyl fluoride, a gaseous [¹⁸ F]fluoride source. Chemical Communications, 2018, 54, 10179-10182.	4.1	23
90	Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. Translational Research, 2018, 199, 24-38.	5.0	13

#	ARTICLE	IF	CITATIONS
91	Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines. Current Radiopharmaceuticals, 2018, 11, 73-75.	0.8	0
92	Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 70-72.	1.0	1
93	Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography. Amino Acids, 2017, 49, 585-595.	2.7	11
94	Evaluation of [¹⁸ F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1286-1298.	4.3	29
95	Pretargeted PET Imaging of <i>trans</i> -Cyclooctene-Modified Porous Silicon Nanoparticles. ACS Omega, 2017, 2, 62-69.	3.5	50
96	Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. Clinical Pharmacokinetics, 2017, 56, 1185-1195.	3.5	19
97	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	2.6	42
98	Fluorine-18 labelled building blocks for PET tracer synthesis. Chemical Society Reviews, 2017, 46, 4709-4773.	38.1	150
99	Stereoselective ¹¹ C Labeling of a Native Tetrapeptide by Using Asymmetric Phase-Transfer Catalyzed Alkylation Reactions. European Journal of Organic Chemistry, 2017, 2017, 1019-1024.	2.4	11
100	A rapid and highly enantioselective C ¹¹ bond formation of <i>l</i> -[¹¹ C]phenylalanine via chiral phase-transfer catalysis. Organic and Biomolecular Chemistry, 2017, 15, 570-575.	2.8	13
101	Consensus nomenclature rules for radiopharmaceutical chemistry – Setting the record straight. Nuclear Medicine and Biology, 2017, 55, v-xi.	0.6	162
102	Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X ₇ Receptor Antagonist. ACS Chemical Neuroscience, 2017, 8, 2374-2380.	3.5	30
103	Synthesis, radiolabeling and preclinical evaluation of a [¹¹ C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor. Nuclear Medicine and Biology, 2017, 51, 25-32.	0.6	9
104	Radiosynthesis of <i>trans</i> -[¹¹ C]methylpropane and <i>trans</i> -[¹¹ C]propanol and its application for alkylation reactions and C-C bond formation. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 566-576.	1.0	2
105	Efficient Synthesis of ¹¹ C-Acylesters, ¹¹ C-Acrylamides and Their Application in Michael Addition Reactions for PET Tracer Development. European Journal of Organic Chemistry, 2017, 2017, 5154-5162.	2.4	8
106	Stereocontrolled [¹¹ C]Alkylation of N-Terminal Glycine Schiff Bases To Obtain Dipeptides. European Journal of Organic Chemistry, 2017, 2017, 5592-5596.	2.4	9
107	Human Dosimetry of the <i>N</i> -Methyl-d-Aspartate Receptor Ligand ¹¹ C-GMOM. Journal of Nuclear Medicine, 2017, 58, 1330-1333.	5.0	2
108	In-vivo monitoring of anti-folate therapy in arthritic rats using [18F]fluoro-PEG-folate and positron emission tomography. Arthritis Research and Therapy, 2017, 19, 114.	3.5	17

#	ARTICLE	IF	CITATIONS
109	Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1925-1936.	3.5	8
110	Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase. <i>Nuclear Medicine and Biology</i> , 2017, 44, 90-104.	0.6	8
111	Parametric Methods for Dynamic ¹¹ C-Phenytoin PET Studies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 479-483.	5.0	2
112	[¹⁸ F]-Labeled Parametric Imaging of Tau Load in Alzheimer's Patients and Controls Using Flortaucipir. <i>Alzheimer's and Dementia</i> , 2017, 13, P1364.	0.8	0
113	[¹⁸ F]-Labeled Parametric Imaging of Tau Load in Alzheimer's Patients and Controls Using Flortaucipir. <i>Alzheimer's and Dementia</i> , 2017, 13, P150.	0.8	0
114	Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques. <i>PLoS ONE</i> , 2017, 12, e0187767.	2.5	22
115	Purinergic receptors P2Y ₁₂ R and P2X ₇ R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2017, 14, 259.	7.2	91
116	Model selection criteria for dynamic brain PET studies. <i>EJNMMI Physics</i> , 2017, 4, 30.	2.7	18
117	Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging. <i>Pharmaceuticals</i> , 2017, 10, 76.	3.8	4
118	Development of [¹¹ C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts. <i>Oncotarget</i> , 2017, 8, 38337-38350.	1.8	7
119	Pharmacokinetic modeling of a novel hypoxia PET tracer [¹⁸ F]HX4 in patients with non-small cell lung cancer. <i>EJNMMI Physics</i> , 2016, 3, 30.	2.7	13
120	Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with [¹⁸ F]-Fluoroazomycin Arabinoside and [¹⁵ O]-H ₂ O PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 530-535.	5.0	13
121	[¹⁸ F]-Labeled Parametric Imaging of Tau Load Using [¹⁸ F]AV-1451 and PET. <i>Alzheimer's and Dementia</i> , 2016, 12, P141.	0.8	0
122	[¹⁸ F]-Labeled Parametric Imaging of Tau Load Using [¹⁸ F]AV-1451 and PET. <i>Alzheimer's and Dementia</i> , 2016, 12, P1109.	0.8	0
123	Bis-pyridylethenyl benzene as novel backbone for amyloid- β binding compounds. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 6139-6148.	3.0	5
124	Two anti-angiogenic TKI-PET tracers, [¹¹ C]axitinib and [¹¹ C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents. <i>Nuclear Medicine and Biology</i> , 2016, 43, 612-624.	0.6	11
125	P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study. <i>AAPS Journal</i> , 2016, 18, 1524-1531.	4.4	21
126	Enantioselective synthesis of carbon-11 labeled l-alanine using phase transfer catalysis of Schiff bases. <i>Tetrahedron</i> , 2016, 72, 6551-6557.	1.9	13

#	ARTICLE	IF	CITATIONS
127	Guidelines to PET measurements of the target occupancy in the brain for drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2255-2262.	6.4	28
128	Parametric Binding Images of the TSPO Ligand ¹⁸ F-DPA-714. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1543-1547.	5.0	23
129	Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 143-160.	5.5	10
130	Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237). <i>Nuclear Medicine and Biology</i> , 2016, 43, 63-72.	0.6	9
131	Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2016, 18, 627-635.	2.6	3
132	Effects of erlotinib therapy on [¹¹ C]erlotinib uptake in EGFR mutated, advanced NSCLC. <i>EJNMMI Research</i> , 2016, 6, 10.	2.5	30
133	Quantification of the novel <i>N</i> -methyl- ¹¹ C-GMOM in man. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1111-1121.	4.3	19
134	Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 425-441.	3.8	63
135	Quantitative and Simplified Analysis of ¹¹ C-Erlotinib Studies. <i>Journal of Nuclear Medicine</i> , 2016, 57, 861-866.	5.0	22
136	Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase. <i>Nuclear Medicine and Biology</i> , 2016, 43, 232-242.	0.6	29
137	A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 62-66.	2.8	50
138	Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: A PET and CMR study. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 1480-1488.	2.1	9
139	Pediatric microdose and microtracer studies using ¹⁴ C in Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 234-237.	4.7	23
140	Bengt Långström-a pioneer in carbon-11 radiochemistry. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 47-48.	1.0	0
141	Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 196-204.	4.7	21
142	Improved synthesis and application of [¹¹ C]benzyl iodide in positron emission tomography radiotracer production. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 342-348.	1.0	12
143	Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier. <i>Molecular Pharmaceutics</i> , 2015, 12, 2265-2275.	4.6	23
144	Feasibility and repeatability of PET with the hypoxia tracer [¹⁸ F]HX4 in oesophageal and pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2015, 116, 94-99.	0.6	44

#	ARTICLE	IF	CITATIONS
145	Quantification of ¹¹ C-Laniquidar Kinetics in the Brain. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1730-1735.	5.0	5
146	Preclinical evaluation of [18F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors. <i>Nuclear Medicine and Biology</i> , 2015, 42, 205-212.	0.6	21
147	Synthesis, structure activity relationship, radiolabeling and preclinical evaluation of high affinity ligands for the ion channel of the N-methyl-d-aspartate receptor as potential imaging probes for positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1189-1206.	3.0	14
148	Synthesis of [³ H]-methyl]temozolomide via <i>in situ</i> activation of hydroxymethyl temozolomide and alkylation with [¹¹ C]methyl iodide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 122-126.	1.0	5
149	Quantification of ¹⁸ F-Fluorocholine Kinetics in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 365-371.	5.0	32
150	[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. <i>Molecular Imaging and Biology</i> , 2015, 17, 615-619.	2.6	40
151	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. <i>Clinical Cancer Research</i> , 2015, 21, 2984-2992.	7.0	95
152	The Dopamine Stabilizer (α)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects. <i>Neuropsychopharmacology</i> , 2015, 40, 472-479.	5.4	22
153	Quantification of [¹⁸ F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 766-772.	4.3	99
154	A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice. <i>EJNMMI Research</i> , 2015, 5, 14.	2.5	38
155	Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 362-371.	4.7	25
156	Use of a Single ¹¹ C-Meta-Hydroxyephedrine Scan for Assessing Flow-Innervation Mismatches in Patients with Ischemic Cardiomyopathy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1706-1711.	5.0	27
157	Quantification of Dynamic ¹¹ C-Phenytoin PET Studies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1372-1377.	5.0	17
158	In Vivo Imaging of Hypoxia in Atherosclerotic Plaques in Humans. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1340-1341.	5.3	31
159	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.	1.1	51
160	The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3B receptors. <i>Neuropharmacology</i> , 2014, 86, 378-388.	4.1	7
161	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.	3.6	37
162	Parametric Methods for Quantification of 18F-FAZA Kinetics in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1772-1777.	5.0	12

#	ARTICLE	IF	CITATIONS
163	Subchronic treatment with phencyclidine in adolescence leads to impaired exploratory behavior in adult rats without altering social interaction or ^{11}C -methylaspartate receptor binding levels. <i>Journal of Neuroscience Research</i> , 2014, 92, 1599-1607.	2.9	4
164	Synthesis and initial preclinical evaluation of the P2X ₇ receptor antagonist [^{11}C]-740003 as a novel tracer of neuroinflammation. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 509-516.	1.0	70
165	Pediatric Microdose Study of [^{14}C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1045-1051.	3.5	29
166	Quantification of [^{11}C]-meta-hydroxyephedrine uptake in human myocardium. <i>EJNMMI Research</i> , 2014, 4, 52.	2.5	27
167	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [^{18}F]HX4 and [^{18}F]FDG-PET/CT Imaging. <i>Clinical Cancer Research</i> , 2014, 20, 6389-6397.	7.0	81
168	Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamides with affinity for GluN2B-containing NMDA receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 828-830.	2.2	17
169	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1190-8.	6.4	7
170	A Universal Procedure for the [^{18}F]Trifluoromethylation of Aryl Iodides and Aryl Boronic Acids with Highly Improved Specific Activity. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 11046-11050.	13.8	84
171	Assessment of Simplified Methods to Measure ^{18}F -FLT Uptake Changes in EGFR-Mutated Non-Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1417-1423.	5.0	17
172	Development of [^{18}F]afatinib as new TKI-PET tracer for EGFR positive tumors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 749-757.	0.6	39
173	EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2175-2185.	6.4	31
174	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R70.	3.5	32
175	Comparison of Simplified Parametric Methods for Visual Interpretation of ^{11}C -Pittsburgh Compound-B PET Images. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1305-1307.	5.0	24
176	Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[^{11}C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 670-680.	0.6	15
177	Polyfluorinated bis-styrylbenzenes as amyloid- β^2 plaque binding ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2469-2481.	3.0	16
178	(R)-[^{11}C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: Evaluation in a rat epilepsy model. <i>Neuropharmacology</i> , 2014, 85, 104-112.	4.1	37
179	PET Imaging of ABC Transporters in the BBB. , 2014, , 625-652.		0
180	Imaging Histamine Receptors Using PET and SPECT. , 2014, , 331-376.		0

#	ARTICLE	IF	CITATIONS
181	Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R37.	3.5	57
182	Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor. <i>EJNMMI Research</i> , 2013, 3, 24.	2.5	10
183	[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors. <i>EJNMMI Research</i> , 2013, 3, 19.	2.5	18
184	Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1523-1531.	6.4	23
185	[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: Impact of epilepsy and drug-responsiveness. <i>Nuclear Medicine and Biology</i> , 2013, 40, 764-775.	0.6	22
186	Impact of molecular imaging on the diagnostic process in a memory clinic. <i>Alzheimer's and Dementia</i> , 2013, 9, 414-421.	0.8	159
187	[11C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer. <i>Nuclear Medicine and Biology</i> , 2013, 40, 488-497.	0.6	24
188	Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. <i>Drug Metabolism and Disposition</i> , 2013, 41, 754-762.	3.3	79
189	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. <i>Neurobiology of Aging</i> , 2013, 34, 128-136.	3.1	145
190	Tumour imaging by Positron Emission Tomography using fluorinase generated 5-[18F]fluoro-5-deoxyribose as a novel tracer. <i>Nuclear Medicine and Biology</i> , 2013, 40, 464-470.	0.6	27
191	Differential effect of <i>APOE</i> genotype on amyloid load and glucose metabolism in AD dementia. <i>Neurology</i> , 2013, 80, 359-365.	1.1	99
192	Radiation Dose of the P-Glycoprotein Tracer ¹¹ C-Laniquidar. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2101-2103.	5.0	12
193	Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2013, 19, 4163-4173.	7.0	58
194	Longitudinal Amyloid Imaging Using ¹¹ C-PiB: Methodologic Considerations. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1570-1576.	5.0	148
195	¹¹ C-labeled and ¹⁸ F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 120-129.	1.0	21
196	Imaging of TKI-Target Interactions for Personalized Cancer Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 239-241.	4.7	15
197	Development of [11C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status. <i>Clinical Cancer Research</i> , 2013, 19, 183-193.	7.0	117
198	In vivo quantification of striatal dopamine D ₂ receptor occupancy by JNJ-37822681 using [¹¹ C]raclopride and positron emission tomography. <i>Journal of Psychopharmacology</i> , 2012, 26, 1128-1135.	4.0	17

#	ARTICLE	IF	CITATIONS
199	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012, 135, 2115-2125.	7.6	109
200	Blood-brain barrier P-glycoprotein function in Alzheimer's disease. <i>Brain</i> , 2012, 135, 181-189.	7.6	252
201	Reproducible Analysis of Rat Brain PET Studies Using an Additional [¹⁸ F]NaF Scan and an MR-Based ROI Template. <i>International Journal of Molecular Imaging</i> , 2012, 2012, 1-10.	1.3	12
202	Altered GABA _A Receptor Density and Unaltered Blood-brain Barrier Transport in a Kainate Model of Epilepsy: An In Vivo Study Using [¹¹ C]-Flumazenil and PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1974-1983.	5.0	26
203	No Evidence for Additional Blood-brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1468-1471.	4.3	18
204	P-Glycoprotein Function at the Blood-brain Barrier: Effects of Age and Gender. <i>Molecular Imaging and Biology</i> , 2012, 14, 771-776.	2.6	127
205	APOE ϵ 4: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, P618.	0.8	0
206	Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012, 33, 1067-1072.	3.1	125
207	Synthesis and preclinical evaluation of [¹¹ C]D617, a metabolite of (R)-[¹¹ C]verapamil. <i>Nuclear Medicine and Biology</i> , 2012, 39, 530-539.	0.6	16
208	PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. <i>Drug Discovery Today</i> , 2012, 17, 1175-1187.	6.4	64
209	[¹¹ C]phenytoin revisited: synthesis by [¹¹ C]CO carbonylation and first evaluation as a P-gp tracer in rats. <i>EJNMMI Research</i> , 2012, 2, 36.	2.5	28
210	Transition metal mediated synthesis using [¹¹ C]CO at low pressure - a simplified method for [¹¹ C]-carbonylation. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 223-228.	1.0	69
211	Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [¹¹ C]AF150(S). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 264-273.	1.0	9
212	Longitudinal imaging of Alzheimer pathology using [¹¹ C]PIB, [¹⁸ F]FDDNP and [¹⁸ F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 990-1000.	6.4	145
213	Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. <i>Cancer Cell</i> , 2012, 21, 82-91.	16.8	307
214	Reproducibility of quantitative (R)-[¹¹ C]verapamil studies. <i>EJNMMI Research</i> , 2012, 2, 1.	2.5	45
215	Insights into imaging in drug discovery and development. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e43-e44.	4.0	1
216	Simultaneous in vivo measurements of receptor density and affinity using [¹¹ C]flumazenil and positron emission tomography: Comparison of full saturation and steady state methods. <i>NeuroImage</i> , 2011, 57, 928-937.	4.2	9

#	ARTICLE	IF	CITATIONS
217	Quantification of the neurokinin 1 receptor ligand [¹¹ C]R116301. Nuclear Medicine Communications, 2011, 32, 896-902.	1.1	4
218	(R)-[¹¹ C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Medical Imaging, 2011, 11, 1.	2.7	43
219	Absolute Quantification of [¹¹ C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography. Clinical Cancer Research, 2011, 17, 4814-4824.	7.0	19
220	Widespread and Prolonged Increase in [¹¹ C]-PK11195 Binding After Traumatic Brain Injury. Journal of Nuclear Medicine, 2011, 52, 1235-1239.	5.0	72
221	Preclinical evaluation and validation of [¹⁸ F]HX4, a promising hypoxia marker for PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14620-14625.	7.1	121
222	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3- ¹⁸ F-fluoro-3-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	7.1	65
223	Biodistribution and radiation dosimetry of ¹¹ C-labelled docetaxel in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1950-1958.	6.4	92
224	Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages. Current Topics in Medicinal Chemistry, 2010, 10, 1820-1833.	2.1	21
225	Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes. Journal of the American College of Cardiology, 2010, 56, 225-233.	2.8	108
226	Relationship of Cerebrospinal Fluid Markers to [¹¹ C]-PiB and [¹⁸ F]-FDDNP Binding. Journal of Nuclear Medicine, 2009, 50, 1464-1470.	5.0	162
227	[⁹ Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology, 2009, 34, 759-766.	5.4	341
228	Detection of Alzheimer Pathology In Vivo Using Both [¹¹ C]-PiB and [¹⁸ F]-FDDNP PET. Journal of Nuclear Medicine, 2009, 50, 191-197.	5.0	119
229	Differential association of [¹¹ C]-PiB and [¹⁸ F]-FDDNP binding with cognitive impairment. Neurology, 2009, 73, 2079-2085.	1.1	45
230	Imaging of Fibrogenesis in Patients with Idiopathic Pulmonary Fibrosis with cis-4-[¹⁸ F]-Fluoro-L-Proline PET. Molecular Imaging and Biology, 2009, 11, 123-127.	2.6	19
231	First Evaluation of [¹¹ C]R116301 as an In Vivo Tracer of NK1 Receptors in Man. Molecular Imaging and Biology, 2009, 11, 241-245.	2.6	8
232	Evaluation of Tracer Kinetic Models for Analysis of [¹⁸ F]-FDDNP Studies. Molecular Imaging and Biology, 2009, 11, 322-333.	2.6	20
233	Test-retest variability of quantitative [¹¹ C]-PiB studies in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1629-1638.	6.4	62
234	Evaluation of [¹¹ C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nuclear Medicine and Biology, 2009, 36, 643-649.	0.6	66

#	ARTICLE	IF	CITATIONS
235	Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. <i>Applied Radiation and Isotopes</i> , 2008, 66, 1414-1418.	1.5	12
236	Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP). <i>Applied Radiation and Isotopes</i> , 2008, 66, 203-207.	1.5	13
237	Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2008, 64, 820-822.	1.3	534
238	³ â€²-Sulfonylestere of 2,5â€²-anhydro-1-(2-deoxy-â€²-d-threo-pentofuranosyl)thymine as precursors for the synthesis of [18F]FLT: syntheses and radiofluorination trials. <i>Nuclear Medicine and Biology</i> , 2008, 35, 413-423.	0.6	14
239	Peripheral metabolism of [18F]FDDNP and cerebral uptake of its labelled metabolites. <i>Nuclear Medicine and Biology</i> , 2008, 35, 869-874.	0.6	24
240	Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 424-433.	4.3	87
241	Quantification of Dopamine Transporter Binding Using [18F]FP-â€²-CIT and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1397-1406.	4.3	34
242	Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2â€²-deoxy-2â€²-[18F]fluoro-d-glucose (FDG) and 3â€²-[18F]fluoro-3â€²-deoxythymidine (FLT). <i>Molecular Imaging and Biology</i> , 2007, 9, 340-347.		43
243	Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand. <i>Nuclear Medicine and Biology</i> , 2006, 33, 801-810.	0.6	29
244	Residual solvent analysis by gas chromatography in radiopharmaceutical formulations containing up to 12% ethanol. <i>Nuclear Medicine and Biology</i> , 2006, 33, 935-938.	0.6	23
245	Synthesis and biodistribution of [11C]R107474, a new radiolabeled â€²-adrenoceptor antagonist. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 4526-4534.	3.0	35
246	Synthesis of N-(3-[18F]Fluoropropyl)-2â€²-carbomethoxy-3â€²-(4-iodophenyl)nortropine ([18F]FP-â€²-CIT). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 77-89.	1.0	14
247	One-pot synthesis of [11C]ureas via triphenylphosphinimines. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 321-330.	1.0	34
248	Synthesis and biodistribution of [11C]R116301, a promising PET ligand for central NK1 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 1579-1586.	3.0	14
249	Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 842-851.	4.3	68
250	Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the bloodâ€²-brain barrier: kinetics and metabolism in the rat. <i>Nuclear Medicine and Biology</i> , 2005, 32, 87-93.	0.6	102
251	Radiosynthesis of [11C]docetaxel. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 763-777.	1.0	17
252	Reductive N-alkylation of secondary amines with [2-11C]acetone. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 1075-1085.	1.0	15

#	ARTICLE	IF	CITATIONS
253	(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. <i>Nuclear Medicine and Biology</i> , 2003, 30, 747-751.	0.6	106
254	Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 1199-1207.	1.0	31
255	Synthesis and pet-studies of (R)-and (S)-[11C]verapamil for measuring PGP function in MDR1A(+)/B(+)/ and MDR1A(-)/B(-) mice. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S313-S315.	1.0	3
256	Radiosynthesis and biodistribution of [¹¹ C]R107474 as a potential pet ligand for central α_2 -adrenoceptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S427.	1.0	3
257	A complete, multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S1052.	1.0	34
258	Characterization of the Binding Site of the Histamine H3Receptor. 2. Synthesis, in Vitro Pharmacology, and QSAR of a Series of Monosubstituted Benzyl Analogues of Thioperamide. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 1754-1761.	6.4	18
259	Evaluation of [¹⁸ F]VUF 5000 as a potential PET ligand for brain imaging of the histamine H3 receptor. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 1761-1767.	3.0	30
260	Synthesis, in vitro pharmacology and radiosynthesis of N-(cis-4-fluoromethylcyclohexyl)-4-(1H-imidazol-4-yl)piperidine-11-thiocarbonamide (VUF 5000), a potential PET ligand for the histamine H3 receptor. , 1999, 42, 293-307.		7
261	Radiosynthesis and biodistribution of ¹²³ I-labeled antagonists of the histamine H3 receptor as potential SPECT ligands. <i>Nuclear Medicine and Biology</i> , 1999, 26, 651-659.	0.6	10
262	Synthesis of radioligands for the histamine H3 receptor. <i>Pharmacochimistry Library</i> , 1998, , 159-174.	0.1	2
263	Brain penetration of the histamine H3 receptor antagonists thioperamide and clobenpropit in rat and mouse, determined with ex vivo [¹²⁵ I]iodophenpropit binding. <i>Brain Research</i> , 1996, 743, 178-183.	2.2	36